DUBLIN--(BUSINESS WIRE)--The "Familial Hypercholesterolemia - Market Insight, Epidemiology and Market Forecast -2030" drug pipelines has been added to ResearchAndMarkets.com's offering.
This report delivers an in-depth understanding of the Familial Hypercholesterolemia (FH), historical and forecasted epidemiology as well as the Familial Hypercholesterolemia (FH) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Familial Hypercholesterolemia (FH) market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Familial Hypercholesterolemia (FH) market size from 2017 to 2030. The report also covers current Familial Hypercholesterolemia (FH) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Familial Hypercholesterolemia (FH) Diagnosis
In general, an estimated 20 million people worldwide have FH. Despite the high prevalence and increased risk of premature ASCVD in untreated patients, less than 1% are diagnosed with FH worldwide.
Family history, physical examination and a lipid profile are essential to establishing a diagnosis of FH. FH should be suspected with fasting LDL-C 190 mg/dL in adults and 160 mg/dL in children if secondary causes of hypercholesterolemia, such as hypothyroidism, nephritic syndrome, and liver disease are ruled out. The presence of xanthomas, corneal arcus, and xanthelasmas before the age of 60 are highly suggestive of FH, more specifically homozygous FH (HoFH), although sitosterolemia should be ruled out as a cause. Individuals affected by homozygous FH possess two mutant alleles at the LDLR, ApoB, PCSK9, or LDLRAP1 gene loci. Individuals may also be genetically compound heterozygotes but may phenotypically look homozygous with severely elevated LDL-C and physical symptoms. Assessment of family history of high LDL-C and premature coronary heart disease is crucial for HoFH diagnosis.
Familial Hypercholesterolemia (FH) Treatment
Early diagnosis and treatment of FH are vital to reduce the risk of premature atherosclerotic cardiovascular disease and death. The goal of treatment is to reduce LDL-C by 50 % from baseline levels with lifestyle modification, pharmacologic lipid-lowering therapy, and LDL apheresis and in rare cases, liver transplantation. People who get only one copy of the defective gene from their parents may do well with diet changes and statin drugs. Pharmacologic treatment ranges from statin medications to newer agents such as lomitapide, mipomersin, and PCSK9 inhibitors. Combination therapy is frequently required to accomplish goal lipoprotein level reductions and prevent complications.
Familial Hypercholesterolemia (FH) Epidemiology
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Prevalent Population of Familial hypercholesterolemia, Diagnosed Prevalent Population of Familial hypercholesterolemia, Mutation-specific Diagnosed Prevalence of Familial hypercholesterolemia and Diagnosed Prevalence of Coronary Heart Disease due to Familial hypercholesterolemia in the 7MM market covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030.
Familial Hypercholesterolemia (FH) Market Outlook
This section of the report includes the dynamics of market scenario for FH in the 7MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
FH is the most common autosomal dominant genetic disease. It is characterized by extremely elevated levels of low-density lipoprotein cholesterol (LDL-C) and a tendency to early-onset atherosclerotic cardiovascular disease. In general, homozygotes manifest the disease at a much earlier age than heterozygotes, and the condition is more severe. It is important to note that if diagnosed, it can be treated with medicines and a healthy lifestyle.
The current market of familial hypercholesterolemia comprises of several treatment options lying in variable classes, such as Statins, Cholesterol absorption inhibitors (Zetia), MTP inhibitors (Juxtapid), APOB antisense inhibitors (Kynamro; mipomersen sodium), PCSK9 inhibitors (Praluent and Repatha), and others (bile-acid-binding resins). In the case of advanced treatment options, Lipoprotein apheresis can also be opted to treat the patients with FH. While in rare and severe cases, patients can also go for liver transplantation.
The pipeline of FH holds potential products by several key players, such as Regeneron Pharmaceuticals (Evinacumab), Novartis (Inclisiran), LIB Therapeutics (LIB003 with Evolocumab), NeuroBo Pharmaceuticals (Gemcabene), Madrigal Pharmaceuticals (Resmetirom), and Arrowhead Pharmaceuticals (ARO-ANG3).
Key Findings
- The market size of Familial Hypercholesterolemia (FH) in the seven major markets is 1,069.27 USD Million in 2017.
- The United States accounts for the largest market size of Familial Hypercholesterolemia (FH), in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.
- Among the EU5 countries, Germany had the highest market size with 84.82 USD Million in 2017. While Spain had the lowest market size of Familial Hypercholesterolemia (FH).
Scope of the Report
- The report covers the descriptive overview of Familial Hypercholesterolemia (FH), explaining its causes, signs and symptoms, pathogenesis and currently available therapies.
- Comprehensive insight has been provided into the Familial Hypercholesterolemia (FH) epidemiology and treatment.
- Additionally, an all-inclusive account of both the current and emerging therapies for Familial Hypercholesterolemia (FH) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
- A detailed review of Familial Hypercholesterolemia (FH) market; historical and forecasted is included in the report, covering the 7MM drug outreach.
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Familial Hypercholesterolemia (FH) market.
Companies Mentioned
- Sanofi/ Regeneron Pharmaceuticals
- Amgen
- Esperion Therapeutics
- Regeneron Pharmaceuticals
- Novartis
- LIB Therapeutics
- NeuroBo Pharmaceuticals
- Madrigal Pharmaceuticals
- Arrowhead Pharmaceutica
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/iev6b7
